SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ALCHEMIA LIMITED (ACL)

Former Name ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

Shareholder links

Our website ranking of ACL: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Link Market Services,Level 21, 10 Eagle Street Brisbane QLD 4000

Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

Address: Level 4 100 Albert Road South Melbourne VIC 3205
Tel:  +61 3 9692 7222 Fax: +61 3 3 9077 9233

Date first listed: 23/12/2003
Company Secretary: Michael Sapountzis
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Development of carbohydrate-based molecules for therapeutic applications

The suspension of trading in the securities of Australian Primary Hemp Limited will lift and the company reinstated to official quotation at the commencement of trading on Friday, 18 October 2019 at 10:00am AEDT, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. The company raised $5,700,000 pursuant to the offer under its replacement prospectus dated 16 September 2019 by the issue of 28,500,000 at an issue price of $0.20 per share.

17/10/2019

name changed to Australian Primary Hemp Limited

15/10/2019

The offers in the replacement prospectus have now closed. The company has successfully raised $5,700,000 through the issue of 28,500,000 fully paid ordinary shares at $0.20 per share. Completion of the share sale agreement between the company, ACN 614 061 951 Pty Ltd and hte shareholders of APH with respect to the acquisition of 100% of the issued capital in APH by the company has now occurred. The company has issued 15,225,000 fully paid ordinary shares to the shareholders of APH as consideration in accordance with the share sale agreement.

03/10/2019

The company has completed the consolidation of its share capital on a one (1) for twenty (20) basis. The consolidation was approved by shareholders at the AGM held on 16 September 2019. The post-consolidation shares of the company are as follows: fully paid ordinary shares - 324,723,621 (pre) - 16,234,845 (post). The consolidation will take effect from 27 September 2019.

27/09/2019

we understand that on or about this date the company consolidated its shares 1 for 20

26/09/2019

The company releases a replacement prospectus to acquire fully paid ordinary shares in Alchemia Limited.

16/09/2019

The company releases the results of its annual general meeting.

16/09/2019

The company releases a notification of consolidation of its securities. Shareholders will get 1 share for every 20 presently owned.

13/09/2019

The company's AGM will be held at Holding Redlich Lawyers, Level 8, 555 Bourke Street, Melbourne VIC 3000 on Monday, 16 September 2019 commencing at 10:00am (Melbourne time).

12/08/2019

The company releases its Appendix 4G and Corporate Governance Statement.

01/08/2019

The company lodges its Appendix 4E and 2019 Annual Report.

01/08/2019

The company lodges an Appendix 4C - Quarterly.

19/07/2019

The company has entered into a share sale agreement pursuant to which it has conditionally agreed to acquire 100% of the issued capital of Australian Primary Hemp. APH is one of Australia's leading hemp producers with a demonstrated execution capability and diversified business operations across the value chain, owning quality production assets in Victoria. APH has a vast network of growers across the east coast of Australia with large scale hemp production capability. Since inception APH's network of growers have procured over 500T of hemp grain. Since the legalisation of hemp in Australia, the industry has experienced rapid growth and APH is strongly positioned to benefit from the growth in hemp demand in Australia and internationally. "¢ Incoming APH executive team and Board of Directors have significant agricultural and hemp industry experience. Alchemia will change its name to "Australian Primary Hemp Limited" on settlement of the acquisition.

21/06/2019

The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 1 July 2019, or when an announcement with regard to ASX's determination is released to the market.

03/06/2019

The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the Company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The Company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 3 June 2019, or when an announcement with regard to ASX's determination is released to the market.

30/04/2019

The company lodges its Appendix 4C - Quarterly.

18/04/2019

The securities of Alchemia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ACL, pending the release of an announcement regarding a proposed change to the nature and scale of the Company's activities.

29/03/2019

The suspension of trading in the securities of Alchemia Limited will be lifted immediately, following the receipt of additional information about the ongoing activities of the Company.

16/06/2016

The company provides an update on company activities.

16/06/2016

The company advises that the ASX has suspended trading of the Company's securities effective close of trading on Tuesday 14 June 2016 due to ASX's opinion that the Company is not in compliance with ASX Listing Rule 12.1. The Company has this morning provided a submission to the ASX to demonstrate its ongoing compliance with Chapter 12 and specifically 12.1 of the Listing Rules. The ASX is currently in the process of reviewing this submission.

15/06/2016

The securities ofAlchemia Limited (the "Company")will be suspended from quotation at the close oftrading today, Tuesday, 14 June 2016 in accordance with listing rule 17.3, as ASX has determined that the Company does not have sufficient operations to warrant the continued quotation of its securities in accordance with listing rule 12.1. The suspension will continue until either the Company is able to demonstrate compliance with Chapter 12 of the Listing Rules, or it complies with Chapters 1 and 2 of the Listing Rules.

14/06/2016

we understand that on or about this date the company made a capital return of 9.3 cents per share

01/02/2016

we understand that on or about this date the company made a capital return of 9.3 cents per share

01/02/2016

The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding the Company's profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL

29/05/2015

The company releases its Fondaparinux Result for Quarter Ended 31 March 2015.

29/05/2015

The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding its profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL

26/05/2015

The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following the Company" update in relation to the proposed demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL

21/12/2012

The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, whilst it continues negotiations relating to the demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL Adrian Smythe

17/12/2012

we understand that on or about this date the company undertook, proposed to undertake or was the subject of the following corporate action: - demerge its wholly owned subsidiary Alchemia Oncology Pty Ltd - this corporate event may appear elsewhere in this company record

18/10/2012

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    08/01/2018David Lamm-48,550,000$0.016$798,309
    04/01/2018Darren Book-256,659$0.021$5,447
    30/06/2017Darren Book1,000,000$0.008$8,000
    12/03/2013Mel Bridges53,750$0.370$19,888
    25/11/2011Mel Bridges94,000$0.320$30,042

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Cameron PetricevicChairman06/06/2018
    James HoodDirector02/10/2019
    Pauline GatelyDirector02/10/2019
    Charles MannDirector02/10/2019

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Melanie LeydinDirector, CFO11/04/201602/10/2019
    Lynden PolonskyDirector04/03/201902/10/2019
    Simon GennariNon Exec Chairman29/02/201604/03/2019
    Darren BookNon Exec Director12/12/201604/03/2019
    David LammNon Exec Director07/03/201606/06/2018
    Nathan DronaNon Exec Director22/03/201325/11/2016
    Tracie RamsdaleNon Exec Director26/04/200729/06/2016
    Jenni PilcherCFO01/09/201411/04/2016
    Ken PoutakidisNon Exec Chairman26/06/201529/02/2016
    Timothy HughesChairman15/07/201309/07/2015
    Santo CostaNon Exec Chairman01/03/201410/06/2015
    Susan KelleyNon Exec Director22/03/201310/06/2015
    Thomas LiquardCEO16/12/201311/11/2014
    Charles WalkerCEO24/02/2014
    Mel BridgesNon Exec Chairman15/07/2013
    Melvyn BridgesNon Exec Chairman02/10/200313/07/2013
    Nerolie WithnallDirector27/10/200304/07/2013
    Peter SmithCEO26/04/200725/01/2013
    Carlo MontagnerNon Exec Director07/03/200822/11/2011
    Peter AndrewsNon Exec Director02/11/199521/11/2008
    Julian ClarkNon Exec Director21/11/2008
    Errol MaltaNon Exec Director27/10/200330/09/2007
    Kevin HealeyNon Exec Director12/03/199818/09/2006
    Nicholas MathiouAlternate Director01/08/2005

    Date of first appointment, title may have changed.